- STAT+: FDA staff and peptide enthusiasts set to clash at advisory panelFDA advisers are set to consider whether allowing compounding pharmacies to offer largely unproven peptides is a safer bet than the gray-market versions now in use.STAT · 1d ago↗ source
- Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clearEli Lilly’s triple-G drug retatrutide has hit the primary endpoints of a pair of phase 3 obesity trials, although the peak weight loss fell short of previous trials while failing to prove the drug…Fierce Biotech · 1d ago↗ source
- Roche Diagnostics growth remains muted amid China headwindsRoche’s Diagnostics division continues to battle growth headwinds, notching a 3% increase in sales.